drug

vortioxetine hydrobromide

Marketedupdated 3mo ago

by Takeda Pharmaceuticals USA Inc

Approved

community read0 votes

indications

investigational

Major Depression

all catalysts(0)

nothing on the calendar yet

Trials studying vortioxetine hydrobromide

phase3Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disordernot yet recruitingn=326

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 23, 2026

3 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (80)

Sep 21, 2032patentUS 9278096*PED
Sep 21, 2032patentUS 9278096*PED
Sep 21, 2032patentUS 9278096*PED
Sep 21, 2032patentUS 9278096*PED
Mar 21, 2032method-of-use (U-2436)US 9278096
Mar 21, 2032method-of-use (U-2436)US 9278096
Mar 21, 2032method-of-use (U-2436)US 9278096
Mar 21, 2032method-of-use (U-2436)US 9278096
Dec 30, 2031patentUS 8722684*PED
Dec 30, 2031patentUS 8722684*PED
Dec 30, 2031patentUS 8722684*PED
Dec 30, 2031patentUS 8722684*PED
Jun 30, 2031compositionUS 87226844.9y
Jun 30, 2031compositionUS 87226844.9y
Jun 30, 2031compositionUS 87226844.9y
Jun 30, 2031compositionUS 87226844.9y
Dec 15, 2027patentUS 11458134*PED1.3y
Dec 15, 2027patentUS 11458134*PED1.3y
Dec 15, 2027patentUS 11458134*PED1.3y
Dec 15, 2027patentUS 11458134*PED1.3y
Dec 15, 2027patentUS 8969355*PED1.3y
Dec 15, 2027patentUS 8969355*PED1.3y
Dec 15, 2027patentUS 8969355*PED1.3y
Dec 15, 2027patentUS 8969355*PED1.3y
Dec 15, 2027patentUS 9125908*PED1.3y
Dec 15, 2027patentUS 9125908*PED1.3y
Dec 15, 2027patentUS 9125908*PED1.3y
Dec 15, 2027patentUS 9125908*PED1.3y
Dec 15, 2027patentUS 9125909*PED1.3y
Dec 15, 2027patentUS 9125909*PED1.3y
Dec 15, 2027patentUS 9125909*PED1.3y
Dec 15, 2027patentUS 9125909*PED1.3y
Dec 15, 2027patentUS 9125910*PED1.3y
Dec 15, 2027patentUS 9125910*PED1.3y
Dec 15, 2027patentUS 9125910*PED1.3y
Dec 15, 2027patentUS 9125910*PED1.3y
Dec 15, 2027patentUS 9227946*PED1.3y
Dec 15, 2027patentUS 9227946*PED1.3y
Dec 15, 2027patentUS 9227946*PED1.3y
Dec 15, 2027patentUS 9227946*PED1.3y
Dec 15, 2027patentUS 9861630*PED1.3y
Dec 15, 2027patentUS 9861630*PED1.3y
Dec 15, 2027patentUS 9861630*PED1.3y
Dec 15, 2027patentUS 9861630*PED1.3y
Jun 15, 2027formulationUS 11458134299d
Jun 15, 2027formulationUS 11458134299d
Jun 15, 2027formulationUS 11458134299d
Jun 15, 2027formulationUS 11458134299d
Jun 15, 2027method-of-use (U-1668)US 8969355299d
Jun 15, 2027method-of-use (U-1668)US 8969355299d
Jun 15, 2027method-of-use (U-1668)US 8969355299d
Jun 15, 2027method-of-use (U-1668)US 8969355299d
Jun 15, 2027method-of-use (U-2309)US 9125908299d
Jun 15, 2027method-of-use (U-2309)US 9125908299d
Jun 15, 2027method-of-use (U-2309)US 9125908299d
Jun 15, 2027method-of-use (U-2309)US 9125908299d
Jun 15, 2027method-of-use (U-2309)US 9125909299d
Jun 15, 2027method-of-use (U-2309)US 9125909299d
Jun 15, 2027method-of-use (U-2309)US 9125909299d
Jun 15, 2027method-of-use (U-2309)US 9125909299d
Jun 15, 2027method-of-use (U-2309)US 9125910299d
Jun 15, 2027method-of-use (U-2309)US 9125910299d
Jun 15, 2027method-of-use (U-2309)US 9125910299d
Jun 15, 2027method-of-use (U-2309)US 9125910299d
Jun 15, 2027method-of-use (U-1668)US 9227946299d
Jun 15, 2027method-of-use (U-1668)US 9227946299d
Jun 15, 2027method-of-use (U-1668)US 9227946299d
Jun 15, 2027method-of-use (U-1668)US 9227946299d
Jun 15, 2027method-of-use (U-1668)US 9861630299d
Jun 15, 2027method-of-use (U-1668)US 9861630299d
Jun 15, 2027method-of-use (U-1668)US 9861630299d
Jun 15, 2027method-of-use (U-1668)US 9861630299d
Dec 17, 2026patentUS 7144884*PED119d
Dec 17, 2026patentUS 7144884*PED119d
Dec 17, 2026patentUS 7144884*PED119d
Dec 17, 2026patentUS 7144884*PED119d
Jun 17, 2026compositionUS 7144884
Jun 17, 2026compositionUS 7144884
Jun 17, 2026compositionUS 7144884
Jun 17, 2026compositionUS 7144884

FDA exclusivities (8)

Feb 23, 2027PEDPediatric (6mo bonus)187d
Feb 23, 2027PEDPediatric (6mo bonus)187d
Feb 23, 2027PEDPediatric (6mo bonus)187d
Feb 23, 2027PEDPediatric (6mo bonus)187d
Aug 23, 2026M-232Method (3y)3d
Aug 23, 2026M-232Method (3y)3d
Aug 23, 2026M-232Method (3y)3d
Aug 23, 2026M-232Method (3y)3d

News(3)

Kolon TissueGene cuts 37 US staffers after Phase 3 fail
Follow along as BioSpace tracks job cuts and restructuring initiatives.
biospace · 12h ago
STAT+: Takeda will pay $13.6 million to settle allegations it paid kickbacks to doctors
Takeda Pharmaceuticals agreed to pay $13.6 million to settle allegations that it paid kickbacks to doctors to prescribe an antidepressant.
stat · 3mo ago
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
fiercebiotech · 7mo ago

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(3)

Kolon TissueGene cuts 37 US staffers after Phase 3 fail

Follow along as BioSpace tracks job cuts and restructuring initiatives.

biospace · 12h ago

STAT+: Takeda will pay $13.6 million to settle allegations it paid kickbacks to doctors

Takeda Pharmaceuticals agreed to pay $13.6 million to settle allegations that it paid kickbacks to doctors to prescribe an antidepressant.

stat · 3mo ago

Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

fiercebiotech · 7mo ago

vortioxetine hydrobromide

indications

all catalysts(0)

Trials studying vortioxetine hydrobromide

Patent cliff

patents (80)

FDA exclusivities (8)

News(3)

Report a data issue

comments(0)

vortioxetine hydrobromide

indications

all catalysts(0)

Trials studying vortioxetine hydrobromide

Patent cliff

patents (80)

FDA exclusivities (8)

News(3)

Report a data issue

comments(0)